Effects of UGT1A1∗6, UGT1A1∗28, and ABCB1-3435C>T polymorphisms on irinotecaninduced toxicity in Chinese cancer patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 54, Issue 3, 2016, Pages 193-199

  Yan, Liang ^a   Wang, Xiao Fei ^a   Wei, Lu Man ^a   Nie, Ya Li ^a   Liu, Jing Yang ^a   Zhang, Li Rong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; UGT1A1 ENZYME;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CHINESE; COLORECTAL CANCER; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SMALL CELL LUNG CANCER; STOMACH CANCER; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; GENETICS; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC;

EID: 84962301190     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202442     Document Type: Article

References (38)

1. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004; 22: 229-237. CrossRef PubMed
2. Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2008; 61: 503-508. CrossRef PubMed
3. Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K. Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study. Oncol Rep. 2009; 21: 1005-1009. CrossRef PubMed
4. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007; 18: 510-517. PubMed
5. Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: A review. Curr Clin Pharmacol. 2010; 5: 209-217. CrossRef PubMed
6. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics. 2010; 11: 1003-1010. CrossRef PubMed
7. Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics. 2010; 11: 391-406. CrossRef PubMed
8. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther. 2004; 75: 501-515. CrossRef PubMed
9. Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, Yoshino S, Okayama N, Hinoda Y, Oka M. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1∗28 polymorphism. Cancer Sci. 2010; 101: 722-727. CrossRef PubMed
10. Tanaka H, Saito K, Mino K, Izumi K, Harada M, Isobe H. [Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan tox icity]. Gan To Kagaku Ryoho. 2009; 36: 1505-1509. PubMed
11. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res. 2000; 60: 6921-6926. PubMed
12. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 1998; 101: 847-854. CrossRef PubMed
13. Mathijssen RH, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001; 7: 2182-2194. PubMed
14. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1∗28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43-47. CrossRef PubMed
15. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1∗6 and∗28. Pharmacogenet Genomics. 2007; 17: 497-504. CrossRef PubMed
16. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B. Role of UGT1A1∗6, UGT1A1∗28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007; 98: 1461-1467. Cross-Ref PubMed
17. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999; 9: 591-599. CrossRef PubMed
18. Sai K, Saito Y. Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs. Expert Opin Drug Metab Toxicol. 2011; 7: 967-988. CrossRef PubMed
19. Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol. 2009; 15: 5058-5066. CrossRef PubMed
20. Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y. UGT1A1∗1/∗28 and∗1/∗6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2011; 68: 279-284. CrossRef PubMed
21. Shulman K, Cohen I, Barnett-Griness O, Kuten A, Gruber SB, Lejbkowicz F, Rennert G. Clinical implications of UGT1A1∗28 genotype testing in colorectal cancer patients. Cancer. 2011; 117: 3156-3162. CrossRef PubMed
22. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003; 13: 741-757. CrossRef PubMed
23. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, Wadelius M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 2011; 11: 61-71. CrossRef PubMed
24. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007; 110: 138-147. Cross-Ref PubMed
25. Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K. UGT1A1∗6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009; 14: 136-142. CrossRef PubMed
26. Liu CY, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Wang WS. UGT1A1∗28 polymorphism predicts irinotecaninduced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940. CrossRef PubMed
27. Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Jpn J Clin Oncol. 2011; 41: 477-482. Cross-Ref PubMed
28. Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol. 2013; 30: 604. CrossRef PubMed
29. Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis. Eur J Cancer. 2010; 46: 1856-1865. CrossRef PubMed
30. Zhang A, Xing Q, Qin S, Du J, Wang L, Yu L, Li X, Xu L, Xu M, Feng G, He L. Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J. 2007; 7: 333-338. Cross-Ref PubMed
31. Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH. Associations between UGT1A1∗6 or UGT1A1∗6/∗28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol. 2014; 73: 779-788. CrossRef PubMed
32. Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miya bayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tada M, Yatomi Y, Koike K. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013; 71: 85-92. CrossRef PubMed
33. Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP. UGT1A1∗6 polymorphisms are correlated with irinotecan-induced toxicity: A system review and meta-analysis in Asians. Cancer Chemother Pharmacol. 2014; 73: 551-560. CrossRef PubMed
34. Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A, Barros F. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemother Pharmacol. 2012; 69: 1591-1599. CrossRef PubMed
35. Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1∗28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians. Pharmacogenomics J. 2014; 14: 120-129. CrossRef PubMed
36. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet. 2003; 42: 59-98. CrossRef PubMed
37. Cortejoso L, García MI, García-Alfonso P, González-Haba E, Escolar F, Sanjurjo M, López-Fernández LA. Differential toxicity biomarkers for irinotecan-and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013; 71: 1463-1472. CrossRef PubMed
38. Cortejoso L, López-Fernández LA. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients. Pharmacogenomics. 2012; 13: 1173-1191. CrossRef PubMed